# A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

> **NCT06890611** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 125 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Bimagrumab
- **DRUG:** Tirzepatide
- **DRUG:** Bimagrumab + Tirzepatide Coformulation

## Key facts

- **NCT ID:** NCT06890611
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-25
- **Primary completion:** 2025-09-26
- **Final completion:** 2025-09-26
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2025-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06890611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06890611, "A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06890611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*